Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30008
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGoldinger, Simone M-
dc.contributor.authorBuder-Bakhaya, Kristina-
dc.contributor.authorLo, Serigne N-
dc.contributor.authorForschner, Andrea-
dc.contributor.authorMcKean, Meredith-
dc.contributor.authorZimmer, Lisa-
dc.contributor.authorKhoo, Chloe-
dc.contributor.authorDummer, Reinhard-
dc.contributor.authorEroglu, Zeynep-
dc.contributor.authorBuchbinder, Elizabeth I-
dc.contributor.authorAscierto, Paolo A-
dc.contributor.authorGutzmer, Ralf-
dc.contributor.authorRozeman, Elisa A-
dc.contributor.authorHoeller, Christoph-
dc.contributor.authorJohnson, Douglas B-
dc.contributor.authorGesierich, Anja-
dc.contributor.authorKölblinger, Peter-
dc.contributor.authorBennannoune, Naima-
dc.contributor.authorCohen, Justine V-
dc.contributor.authorKähler, Katharina C-
dc.contributor.authorWilson, Melissa A-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorAtkinson, Victoria-
dc.contributor.authorSmith, Jessica L-
dc.contributor.authorMichielin, Olivier-
dc.contributor.authorLong, Georgina V-
dc.contributor.authorHassel, Jessica C-
dc.contributor.authorWeide, Benjamin-
dc.contributor.authorHaydu, Lauren E-
dc.contributor.authorSchadendorf, Dirk-
dc.contributor.authorMcArthur, Grant-
dc.contributor.authorOtt, Patrick A-
dc.contributor.authorBlank, Christian-
dc.contributor.authorRobert, Caroline-
dc.contributor.authorSullivan, Ryan-
dc.contributor.authorHauschild, Axel-
dc.contributor.authorCarlino, Matteo S-
dc.contributor.authorGarbe, Claus-
dc.contributor.authorDavies, Michael A-
dc.contributor.authorMenzies, Alexander M-
dc.date2021-
dc.date.accessioned2022-06-22T06:47:43Z-
dc.date.available2022-06-22T06:47:43Z-
dc.date.issued2022-02-
dc.identifier.citationEuropean Journal of Cancer (Oxford, England : 1990) 2022; 162: 22-33en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30008-
dc.description.abstractDespite remarkably improved outcomes with immune checkpoint inhibition, many patients with metastatic melanoma will eventually require further therapy. Chemotherapy has limited activity when used first-line but can alter the tumour microenvironment and does improve efficacy when used in combination with immunotherapy in lung cancer. Whether chemotherapy after checkpoint inhibitor failure has relevant activity in patients with metastatic melanoma is unknown. Patients with metastatic melanoma treated with chemotherapy after progression on immunotherapy with checkpoint inhibitors were identified retrospectively from 24 melanoma centres. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and safety were examined. In total, 463 patients were treated between 2007 and 2017. Fifty-six per cent had received PD-1-based therapy before chemotherapy. Chemotherapy regimens included carboplatin + paclitaxel (32%), dacarbazine (25%), temozolomide (15%), taxanes (9%, nab-paclitaxel 4%), fotemustine (6%) and others (13%). Median duration of therapy was 7.9 weeks (0-108). Responses included 0.4% complete response (CR), 12% partial response (PR), 21% stable disease (SD) and 67% progressive disease (PD). Median PFS was 2.6 months (2.2, 3.0), and median PFS in responders was 8.7 months (6.3, 16.3), respectively. Twelve-month PFS was 12% (95% CI 2-15%). In patients who had received anti-PD-1 before chemotherapy, the ORR was 11%, and median PFS was 2.5 months (2.1, 2.8). The highest activity was achieved with single-agent taxanes (N = 40), with ORR 25% and median PFS 3.9 months (2.1, 6.2). Median OS from chemotherapy start was 7.1 months (6.5, 8.0). Subsequent treatment with checkpoint inhibitors achieved a response rate of 16% with a median PFS of 19.1 months (2.0-43.1 months). No unexpected toxicities were observed. Chemotherapy has a low response rate and short PFS in patients with metastatic melanoma who have failed checkpoint inhibitor therapy, although activity varied between regimens. Chemotherapy has a limited role in the management of metastatic melanoma.en
dc.language.isoeng
dc.subjectAnti-PD-1 antibodiesen
dc.subjectCanceren
dc.subjectCheckpoint inhibitorsen
dc.subjectChemotherapyen
dc.subjectImmunotherapyen
dc.subjectMelanomaen
dc.titleChemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.en
dc.typeJournal Articleen
dc.identifier.journaltitleEuropean Journal of Cancer (Oxford, England : 1990)en
dc.identifier.affiliationUniversity of Zurich, Department of Dermatology, Gloriastrasse 31 Zurich, 8091, Switzerland..en
dc.identifier.affiliationMelanoma Institute Australia, The University of Sydney, The Poche Centre, 40 Rocklands Road North Sydney NSW 2060, Australia..en
dc.identifier.affiliationUniversity Hospital Heidelberg, Department of Dermatology and National Center for Cancer (NCT), Im Neuenheimer Feld 460 Heidelberg, 69120, Germany..en
dc.identifier.affiliationUniversity of Tuebingen, Department of Dermatology, Liebermeisterstrasse 25, Tübingen, 72076, Germany..en
dc.identifier.affiliationUniversity of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology and Department of Surgical Oncology, 1400 Pressler Street, Houston, TX 77006 USA..en
dc.identifier.affiliationUniversity Hospital Essen, Department of Dermatology, Essen & German Cancer Consortium, Partner Site Essen, Germany..en
dc.identifier.affiliationPeter MacCallum Cancer Centre, Melbourne, Australia..en
dc.identifier.affiliationMoffitt Cancer Center, Department of Cutaneous Oncology, 12902 Magnolia Drive, Tampa, FL 33612, USA..en
dc.identifier.affiliationDana Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA..en
dc.identifier.affiliationDepartment of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Napoli, Italy..en
dc.identifier.affiliationSkin Cancer Center, Department of Dermatology, Mühlenkreiskliniken, Ruhr University Bochum Campus Minden, Germany..en
dc.identifier.affiliationAntoni van Leeuwenhoek Hospital - The Netherlands Cancer Institute, Department of Medical Oncology and Immunology, Plesmanlaan 121 Amsterdam, 1066 CX, the Netherlands..en
dc.identifier.affiliationMedical University of Vienna, Department of Dermatology, Waehringer Guertel 18-20, Vienna, 1090, Austria..en
dc.identifier.affiliationVanderbilt University Medical Center, Department of Medicine, Nashville, TN, USA..en
dc.identifier.affiliationUniversity Hospital Wuerzburg, Department of Dermatology, Wuerzburg, Germany..en
dc.identifier.affiliationDepartment of Dermatology and Allergology, Paracelsus Medical University, Salzburg, Austria..en
dc.identifier.affiliationGustave Roussy and Paris-Saclay University, 114 rue Edouard Vaillant Villejuif Cedex, 94805, France..en
dc.identifier.affiliationMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA..en
dc.identifier.affiliationDepartment of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Arnold-Heller-Strasse 3, Haus C, Kiel, 24105, Germany..en
dc.identifier.affiliationPerlmutter Cancer Center, NYU Langone Health, NYU School of Medicine, 160 E. 34th Street, New York, NY 10016, USA..en
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationUniversity of QLD, Princess Alexandra Hospital, Greenslopes Private Hospital, 199 Ipswich Rd, Woolloongabba QLD 4102, Australia..en
dc.identifier.affiliationCrown Princess Mary Cancer Centre Westmead, Sydney, NSW, Australia..en
dc.identifier.affiliationLausanne University Hospital, Department of Oncology, Precision Oncology Center, Rue du Bugnon 21, Lausanne, 1011, Switzerland..en
dc.identifier.affiliationMelanoma Institute Australia, The University of Sydney, The Poche Centre, 40 Rocklands Road North Sydney NSW 2060, Australia..en
dc.identifier.affiliationRoyal North Shore Hospital, Reserve Road St Leonards NSW 2065, Australia..en
dc.identifier.affiliationMater Hospital, 25 Rocklands Road, North Sydney NSW 2060, Australia..en
dc.identifier.affiliationFaculty of Medicine and Health, The University of Sydney, Sydney, Australia..en
dc.identifier.affiliationCharles Perkins Centre, The University of Sydney, Australia..en
dc.identifier.affiliationUniversity Hospital Heidelberg, Department of Dermatology and National Center for Cancer (NCT), Im Neuenheimer Feld 460 Heidelberg, 69120, Germany..en
dc.identifier.affiliationUniversity of Tuebingen, Department of Dermatology, Liebermeisterstrasse 25, Tübingen, 72076, Germany..en
dc.identifier.affiliationUniversity of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology and Department of Surgical Oncology, 1400 Pressler Street, Houston, TX 77006 USA..en
dc.identifier.affiliationUniversity Hospital Essen, Department of Dermatology, Essen & German Cancer Consortium, Partner Site Essen, Germany..en
dc.identifier.affiliationPeter MacCallum Cancer Centre, Melbourne, Australia..en
dc.identifier.affiliationDana Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA..en
dc.identifier.affiliationAntoni van Leeuwenhoek Hospital - The Netherlands Cancer Institute, Department of Medical Oncology and Immunology, Plesmanlaan 121 Amsterdam, 1066 CX, the Netherlands..en
dc.identifier.affiliationGustave Roussy and Paris-Saclay University, 114 rue Edouard Vaillant Villejuif Cedex, 94805, France..en
dc.identifier.affiliationMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA..en
dc.identifier.affiliationDepartment of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Arnold-Heller-Strasse 3, Haus C, Kiel, 24105, Germany..en
dc.identifier.affiliationCrown Princess Mary Cancer Centre Westmead, Sydney, NSW, Australia..en
dc.identifier.affiliationUniversity of Tuebingen, Department of Dermatology, Liebermeisterstrasse 25, Tübingen, 72076, Germany..en
dc.identifier.affiliationUniversity of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology and Department of Surgical Oncology, 1400 Pressler Street, Houston, TX 77006 USA..en
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/34952480/en
dc.identifier.doi10.1016/j.ejca.2021.11.022en
dc.type.contentTexten
dc.identifier.orcid0000-0002-3898-950Xen
dc.identifier.pubmedid34952480
local.name.researcherCebon, Jonathan S
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.